^
    4ms
    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=22, Active, not recruiting, Prelude Therapeutics | Recruiting --> Active, not recruiting | N=61 --> 22
    Enrollment closed • Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    KRAS mutation • ER positive • HER-2 negative • TP53 wild-type • CDKN2A deletion • RAS wild-type • SMARCA4 mutation • IDH wild-type
    |
    PRT3645
    1year
    The brain penetrant CDK4/6 Inhibitor, PRT3645, is highly effective in combination with other targeted therapies in preclinical models of NSCLC, CRC, and HER2-positive breast cancer (AACR 2023)
    In preclinical studies, PRT3645 was highly efficacious when combined with KRAS/MEK inhibitors, and with a brain penetrant HER2 receptor TKI, both in-vitro and in-vivo. PRT3645 has advanced into Phase 1 clinical trials (NCT05538572).
    Preclinical • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • CDK6 (Cyclin-dependent kinase 6) • CDK9 (Cyclin Dependent Kinase 9) • CDK1 (Cyclin-dependent kinase 1)
    |
    HER-2 positive • KRAS mutation • HER-2 negative • CDKN2A deletion • KRAS deletion
    |
    PRT3645
    over1year
    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=51, Recruiting, Prelude Therapeutics | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    KRAS mutation • HER-2 negative • CDKN2A deletion • RAS wild-type • IDH wild-type
    |
    PRT3645
    over1year
    A Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=51, Not yet recruiting, Prelude Therapeutics
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B)
    |
    KRAS mutation • HER-2 negative • CDKN2A deletion • RAS wild-type • IDH wild-type
    |
    PRT3645